The German pharmaceutical company CureVac has revealed the frustrations of mRNA tests Covid-19 vaccine, diminishing the hope that the jab could help meet the global demand for appropriate inococations.
CureVac on Wednesday said its jab was 47% effective in protecting against coronavirus during a temporary trial of its trial, making it one of the lowest vaccines tested so far.
Earlier this week, Novavax drug maker said his gun from the protein was 90% effective in the fight against coronavirus where Moderna and BioNTech / Pfizer jabs have a 95 percent effectiveness in treating the initial viral problem.
Nasdaq’s CureVac shares accounted for a 50% drop in the New York stock market.
The company said the negative effects were due to new strains of the virus that spread to 10 countries across Latin America and Europe, where tests were being conducted.
In a study of 40,000 people, TreatmentVac says 13 species were found in volunteers, more than half of coronavirus cases caused by several types of anxiety.
However, data from the UK this week revealed that the BioNTech / Pfizer vaccine for mRNA, or messenger ribonucleic acid, vaccinated was 96 percent effective in preventing hospitalization for people with Delta, which was first discovered in India.
This week, the U.S. Centers for Disease Control and Prevention added to the Delta crisis in a series of crisis cases.
CureVac has teamed up with German equipment manufacturer Bayer to develop a coronavirus vaccine and is partnering with British pharma company GlaxoSmithKline to create the next generation of jabs.
The results of weak efforts make the works questionable. CureVac plans to launch the 300m vaccine this year and 1bn by 2022.
“While we expect the small results to be strong, we realize that showing great performance on these unprecedented variables is a challenge,” said Franz-Werner Haas, chief executive of CureVac. He added that many species “confirm the need to develop a future vaccine”.
The vaccine is also being considered in the UK as part of a pilot trial that offers a wide range of Oxford / AstraZeneca or BioNTech / Pfizer vaccine recipients.
Like Moderna and BioNTech / Pfizer vaccines, CureVac jab uses mRNA but its mRNA is natural and unchanged. Its shots also use a smaller dose, 12 micrograms compared to 100mg of Moderna and BioNTech / Pfizer’s 30mg, which results in lower prices, and are more stable in hot refrigerators.
CureVac will continue to test its two-group mRNA vaccine and will select the most appropriate method after conducting a final pilot study.
Coronavirus business transformation
How do coronaviruses treat problems in markets, businesses, in our daily lives and in the workplace? Be brief with our article on coronavirus mail. Sign in here
Source link
